Matches in SemOpenAlex for { <https://semopenalex.org/work/W2242183195> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2242183195 endingPage "14620" @default.
- W2242183195 startingPage "14620" @default.
- W2242183195 abstract "14620 Background: Satraplatin is a novel oral platinum analog with potent cytotoxic and antitumor activity in preclinical models. Satraplatin showed activity in hormone refractory prostate cancer (HRPC) and other tumor types in Phase II trials. A pivotal Phase III trial evaluating satraplatin as 2 nd -line therapy for HRPC completed accrual of > 900 patients in 2005. Satraplatin’s activity, safety profile and ease of administration make it attractive for combination regimens. Methods: Satraplatin and its active metabolite JM-118 were tested in vitro as single agents in the androgen-sensitive LNCaP and the androgen-insensitive PC-3 and DU-145 human prostate carcinoma (ca.) cell lines. For in vitro combination studies, PC-3 cells were treated with satraplatin or JM-118 either prior to, after, or concomitantly with paclitaxel or docetaxel. The PC-3 cell line was used for in vivo xenograft experiments in nude mice. Paclitaxel was given intravenously on Day 1, satraplatin orally on Days 2 to 6, and paclitaxel again on Day 8. Results: Satraplatin and JM-118 as single agents inhibited the growth of all three prostate ca. cell lines in vitro in a dose dependent fashion. IC 50 values for JM-118 were < 1μM. Strong synergism was noted when PC-3 tumor cells were treated in vitro with paclitaxel or docetaxel followed by satraplatin or JM-118. Satraplatin administered orally inhibited the growth of PC-3 xenografts in nude mice. Treatment of advanced PC-3 tumors with paclitaxel (40 mg/kg) and satraplatin (35 mg/kg) was well tolerated and resulted in a Tumor Growth Delay equivalent to 3 Log Cell Kill, an effect superior to that of the single agents. Conclusions: In vitro, satraplatin and its metabolite JM-118 are active as single agents against human prostate ca. cells, and are synergistic with taxanes. In vivo, treatment with paclitaxel followed by satraplatin showed synergism without increased toxicity. These preclinical data support ongoing Phase I and II clinical trials that are evaluating combinations of satraplatin with paclitaxel or docetaxel. [Table: see text]" @default.
- W2242183195 created "2016-06-24" @default.
- W2242183195 creator A5002727775 @default.
- W2242183195 creator A5006302329 @default.
- W2242183195 creator A5034579994 @default.
- W2242183195 creator A5036969911 @default.
- W2242183195 creator A5044755763 @default.
- W2242183195 creator A5052997517 @default.
- W2242183195 creator A5067813566 @default.
- W2242183195 date "2006-06-20" @default.
- W2242183195 modified "2023-09-25" @default.
- W2242183195 title "Satraplatin, an oral platinum analog, is active and synergistic with paclitaxel and docetaxel in prostate carcinoma models" @default.
- W2242183195 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.14620" @default.
- W2242183195 hasPublicationYear "2006" @default.
- W2242183195 type Work @default.
- W2242183195 sameAs 2242183195 @default.
- W2242183195 citedByCount "3" @default.
- W2242183195 countsByYear W22421831952013 @default.
- W2242183195 crossrefType "journal-article" @default.
- W2242183195 hasAuthorship W2242183195A5002727775 @default.
- W2242183195 hasAuthorship W2242183195A5006302329 @default.
- W2242183195 hasAuthorship W2242183195A5034579994 @default.
- W2242183195 hasAuthorship W2242183195A5036969911 @default.
- W2242183195 hasAuthorship W2242183195A5044755763 @default.
- W2242183195 hasAuthorship W2242183195A5052997517 @default.
- W2242183195 hasAuthorship W2242183195A5067813566 @default.
- W2242183195 hasConcept C121608353 @default.
- W2242183195 hasConcept C126322002 @default.
- W2242183195 hasConcept C150903083 @default.
- W2242183195 hasConcept C185592680 @default.
- W2242183195 hasConcept C202751555 @default.
- W2242183195 hasConcept C207001950 @default.
- W2242183195 hasConcept C2776235491 @default.
- W2242183195 hasConcept C2776694085 @default.
- W2242183195 hasConcept C2777292972 @default.
- W2242183195 hasConcept C2779723316 @default.
- W2242183195 hasConcept C2780192828 @default.
- W2242183195 hasConcept C2781190966 @default.
- W2242183195 hasConcept C55493867 @default.
- W2242183195 hasConcept C71924100 @default.
- W2242183195 hasConcept C86803240 @default.
- W2242183195 hasConcept C98274493 @default.
- W2242183195 hasConceptScore W2242183195C121608353 @default.
- W2242183195 hasConceptScore W2242183195C126322002 @default.
- W2242183195 hasConceptScore W2242183195C150903083 @default.
- W2242183195 hasConceptScore W2242183195C185592680 @default.
- W2242183195 hasConceptScore W2242183195C202751555 @default.
- W2242183195 hasConceptScore W2242183195C207001950 @default.
- W2242183195 hasConceptScore W2242183195C2776235491 @default.
- W2242183195 hasConceptScore W2242183195C2776694085 @default.
- W2242183195 hasConceptScore W2242183195C2777292972 @default.
- W2242183195 hasConceptScore W2242183195C2779723316 @default.
- W2242183195 hasConceptScore W2242183195C2780192828 @default.
- W2242183195 hasConceptScore W2242183195C2781190966 @default.
- W2242183195 hasConceptScore W2242183195C55493867 @default.
- W2242183195 hasConceptScore W2242183195C71924100 @default.
- W2242183195 hasConceptScore W2242183195C86803240 @default.
- W2242183195 hasConceptScore W2242183195C98274493 @default.
- W2242183195 hasIssue "18_suppl" @default.
- W2242183195 hasLocation W22421831951 @default.
- W2242183195 hasOpenAccess W2242183195 @default.
- W2242183195 hasPrimaryLocation W22421831951 @default.
- W2242183195 hasRelatedWork W190801549 @default.
- W2242183195 hasRelatedWork W2000433012 @default.
- W2242183195 hasRelatedWork W2014434161 @default.
- W2242183195 hasRelatedWork W2032666512 @default.
- W2242183195 hasRelatedWork W2094434087 @default.
- W2242183195 hasRelatedWork W2169384475 @default.
- W2242183195 hasRelatedWork W2185291512 @default.
- W2242183195 hasRelatedWork W2323860656 @default.
- W2242183195 hasRelatedWork W2589361923 @default.
- W2242183195 hasRelatedWork W4362587084 @default.
- W2242183195 hasVolume "24" @default.
- W2242183195 isParatext "false" @default.
- W2242183195 isRetracted "false" @default.
- W2242183195 magId "2242183195" @default.
- W2242183195 workType "article" @default.